Wed, September 5, 2012
Tue, September 4, 2012
Mon, September 3, 2012
Sun, September 2, 2012
Sat, September 1, 2012
Fri, August 31, 2012
Thu, August 30, 2012
Wed, August 29, 2012
Tue, August 28, 2012
Mon, August 27, 2012
Sun, August 26, 2012
Sat, August 25, 2012
Fri, August 24, 2012
Thu, August 23, 2012
Wed, August 22, 2012
[ Wed, Aug 22nd 2012 ] - Market Wire
Inergetics Shareholder Update
Tue, August 21, 2012

Regeneron Announces September 2012 Investor Conference Presentations


//health-fitness.news-articles.net/content/2012/ .. mber-2012-investor-conference-presentations.html
Published in Health and Fitness on Wednesday, August 29th 2012 at 7:03 GMT by Market Wire   Print publication without navigation


Regeneron Announces September 2012 Investor Conference Presentations -- TARRYTOWN, N.Y., Aug. 29, 2012 /PRNewswire/ --

Regeneron Announces September 2012 Investor Conference Presentations

TARRYTOWN, N.Y., Aug. 29, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:

  • Robert W. Baird Healthcare Conference at 1:20 p.m. Eastern Time on Wednesday, September 5, 2012
  • Morgan Stanley Global Healthcare Conference at 3:55 p.m. Eastern Time on Tuesday, September 11, 2012
  • UBS Global Life Sciences Conference at 7:30 a.m. Eastern Time on Thursday, September 20, 2012

The sessions may be accessed through the Company's web site, [ www.regeneron.com ], on the Events and Presentations page.  Archived versions of the presentations will be available for thirty days after the live webcasts. 

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets three products in the United States, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use.  Regeneron has filed a regulatory application with the U.S. Food and Drug Administration (FDA) for a second indication for EYLEA.  Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.  Additional information and recent news releases are available on the Regeneron web site at [ www.regeneron.com ].

Contact Information:


Manisha Narasimhan, Ph.D.

Peter Dworkin

Investor Relations

Corporate Communications                           

914-847-5126

914.847.7640             

[ manisha.narasimhan@regeneron.com

[ peter.dworkin@regeneron.com ]

SOURCE Regeneron Pharmaceuticals, Inc.



[ Back to top ]

RELATED LINKS
[ http://www.regeneron.com ]


Publication Contributing Sources